Therefore, based on the above results, we have good reasons to believe that the PPAR-γ signaling pathway may regulate melanogenesis by altering the expression of ENDRB, and rosiglitazone, a specific agonist of PPAR-γ, may become a potential target for non-segmental vitiligo treatment. This evidence concerns the gene PPARG and vitiligo.